Should I buy GE HealthCare (GEHC) stock or is it too late?

GE HealthCare · Health Care · price $72

See the full GE HealthCare (GEHC) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $70 (-3.4 %), call made on July 10, 2026, maturing on July 10, 2027 (49 d ago).

The 5 reliable analysts $75+3.5 %

The 8 other firms $79+9.0 %

How to read it: the 5 reliable firms are not filtered by optimism — 4 aim above the price, 1 below, hence their $75 median. “The 8 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on GE HealthCare

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Mizuho	50 %	-0.9 %	6	$90 +24%
Citigroup	17 %	-5.7 %	6	$75 +3%

In short — Should you invest in GE HealthCare? Is it too late, still worth it? Analysts are split (46% buy, median target $79, i.e. +8%), and the most reliable on GEHC targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $79, i.e. +8% from the current price ($72).
The most reliable firm on GEHC, UBS (50% hit rate, 2 scored calls), targets $73 (call made on July 31, 2026, maturing on July 31, 2027) (+1%) in its most recent call, and $77 (call made on January 15, 2026, maturing on January 15, 2027) (+6%) in the one coming due soonest.
Reasonable valuation (P/E ~17) relative to its sector.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 7 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
Negligible dividend (0.2% yield): your return depends mostly on price appreciation.

The analyst consensus on GEHC

Median target $79 (+8%) · 13 ratings · Hold consensus

Strong Buy00%

Buy646%

Hold754%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in GE HealthCare now?

We won't decide for you. The facts: 46% of analysts rate it a buy, median target $79 (+8%), and UBS (most reliable on GEHC, 50%) targets $73. Weigh that against valuation (P/E ~17). This is not personalized advice.

Is it too late to invest in GE HealthCare?

Not according to analysts: the median target ($79) is still +8% above the current price ($72) (most reliable on GEHC: UBS, 50%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is GE HealthCare still worth investing in?

It depends on the gap between the price ($72) and its estimated value: analysts target $79 on median (+8%), with 46% buys (most reliable on GEHC: UBS, 50%). Cross-check with their real reliability on GEHC and the cautions above. Information, not advice.

What's the main risk in buying GEHC?

The consensus is not unanimous: of 13 ratings, 7 are neutral.

→ Go deeper: the full GE HealthCare profile (consensus, analyst reliability, price target, performance).